medigraphic.com
Colegio de Medicina Interna de México.

2014, Number 5

<< Back Next >>

Med Int Mex 2014; 30 (5)

Glucose control in patients attending to education program DiabetIMSS in Tecate, Baja California, Mexico

Romero-Valenzuela E, Zonana-Nacach A, Colín-García MÁ

Language: Spanish
References: 29
Page: 554-561
PDF size: 432.78 Kb.


ABSTRACT

Background: Nowadays diabetes mellitus is the most common chronic disease and a little proportion of patients has an adequate metabolic control in developed countries, as well as in Latin America or Mexico.
Objective: To assess the metabolic control in patients enrolled in the multidisciplinary and group educational program DiabetIMSS.
Methods: A retrospective study was made in which clinical charts of diabetes mellitus type 2 patients enrolled in the DiabetIMSS program during 2010-2011 at a primary care unit in Tecate, Mexico, were reviewed. An adequate metabolic control was defined as a fasting blood glucose ≤ 130 mg/dL.
Results: In a mean period of 8.4 months 698 patients assisted to DiabetIMSS program and 531 had complete glucose values at the beginning and at the end of the program. The fasting blood glucose decreased significantly (165.4 ± 72.9 a 153.6 ± 67.6 mg/dL, p = 0.002). The percentage of patients with an adequate metabolic control increased from 39.7% to 47.3%. Patients with adequate metabolic control were more frequently women (53% vs 47%, p = 0.01), older (55.8% vs 53 years, p = 0.04) and had lower disease duration (73 vs 98 months, p = 0.001). Two hundred eighty one (53%) patients lost weight, mean 2.9 kg.
Conclusions: There was a good adherence to DiabetIMSS program, since 77% of patients stayed for ≥ 6 months. Patients in DiabetIMSS had a higher frequency of adequate metabolic control than diabetic patients who have been received usual individual care in Mexico or other countries.


REFERENCES

  1. Villalpando S, Shamah-Levy T, Rojas R, Aguilar-Salinas CA. Trends for type 2 diabetes and other cardiovascular risk factors in Mexico from 1993-2006. Salud Pública Méx 2010;52:S72-S79.

  2. Escobedo de la Peña J, Buitrón-Granados LV, Ramírez- Martínez JC, Chavira-Mejía R, et al. Diabetes in Mexico. CARMELA study. Cir Cir 2011;79:424-431.

  3. Rodríguez Bolaños R de L, Reynales Shigematsu LM, Jiménez Ruíz JA, Juárez Márquezy SA, Hernández Avila M. Direct costs of medical care for patients with type 2 diabetes mellitus in Mexico micro-costing analysis. Rev Panam Salud Publica 2010;28:412-420.

  4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33): UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-853.

  5. Stratton IM, Adler AI, Andrew H, Neil W, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412.

  6. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10- year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589

  7. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004;291:335-342.

  8. Gagliardino JJ, De la Hera M, Siri F, Grupo de Investigación de la red QUALIDIAB. Evaluation of the quality of care for diabetic patients in Latin America. Rev Panam Salud Pública 2001;10:309-317.

  9. González-Villalpando C, López-Ridaura R, Campuzano JC, González-Villalpando ME. The status of diabetes care in Mexican population: are we making a difference? Results of the National Health and Nutrition Survey 2006. Salud Púb Méx 2010;52:S36-S43.

  10. Villalpando S, De la Cruz V, Rojas R, Shamah-Levy T, et al. Prevalence and distribution of type 2 diabetes mellitus in Mexican adult population: a probabilistic survey. Salud Púb Méx 2010;52:S19-S26.

  11. Fanghänel-Salmón G, Sánchez-Reyes L, Chiquete Anaya E, de la Luz Castro J, Escalante Herrera A. Multicenter international registry to evaluate the clinical practice delivered to patients with type 2 diabetes mellitus: a sub-analysis of the experience in Mexico. Gac Méd Méx 2011;147:226-233.

  12. Lavalle-González FJ, Chiquete E, de la Luz J, Ochoa-Guzmán A, et al. Achievement of therapeutic targets in Mexican patients with diabetes mellitus. Endocrinol Nutr 2012;59:591-598.

  13. Jaber R, Braksmajer A, Trilling J. Group visits for chronic illness care: models, benefits and challenges. Fam Pract Manag 2006;13:37-40.

  14. Salinas-Martínez AM, Garza-Sagástegui MG, Cobos-Cruz R, Núñez-Rocha GM, et al. Effects of incorporating group visits on the metabolic control of type 2 diabetic patients. Rev Med Chil 2009;137:1323-1332.

  15. Stern E, Benbassat CA, Goldfracht M. Impact of a two-arm educational program for improving diabetes care in primary care centers. Int J Clin Pract 2005;59:1126-1130.

  16. Kim MY, Suh S, Jin SM, Kim SW, et al. Education as prescription for patients with type 2 diabetes mellitus: compliance and efficacy in clinical practice. Diabetes Metab J 2012;36:452-459.

  17. Trento M, Passera P, Tomalino M, Bajardi M, Pomero F, Allione A, et al. Group visits improve metabolic control in type 2 diabetes: a 2-year follow-up. Diabetes Care 2001;24:995-1000.

  18. Balamurugan A, Rivera M, Jack L Jr, et al. Barriers to diabetes self-management education programs in underserved rural Arkansas: implications for program evaluation. Prev Chronic Dis 2006;3:A15.

  19. Ma J, Yank V, Xiao L, Lavori PW, et al. Translating the diabetes prevention program lifestyle intervention for weight loss into primary care: a randomized trial. JAMA Intern Med 2013;173:113-121.

  20. D’Eramo-Melkus GA, Wylie-Rosett J, Hagan JA. Metabolic impact of education in NIDDM. Diabetes Care 1992;15:864- 869.

  21. Ostermann H, Hoess V, Mueller M. Efficiency of the Austrian disease management program for diabetes mellitus type 2: a historic cohort study based on health insurance provider’s routine data. BMC Public Health 2012;12:490.

  22. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-591.

  23. Rasekaba TM, Graco M, Risteski C, Jasper A, et al. Impact of a diabetes disease management program on diabetes control and patient quality of life. Popul Health Manag 2012;15:12-19.

  24. Gil-Velázquez L, Sil-Acosta M, Domínguez SE, Torres-Arreola LP. Guía de práctica clínica. Diagnóstico y tratamiento de la diabetes mellitus tipo 2. Disponible en: http://wwww.imss. gob.mx/profesionales/guiasclinicas/Documents/000GER_ DiabetesMellitus.pdf .

  25. Gil-Velázquez LE, Sil-Acosta MJ, Aguilar-Sánchez L, Echevarria- Zuno S, et al. Perspective on type 2 diabetes mellitus in the Instituto Mexicano del Seguro Social. Rev Med Inst Mex Seguro Soc 2013;51:58-67.

  26. Gamiochipi M, Haua NK, Valdez GL, Vázquez EF y col. Programa de educación en diabetes. México: Dirección de Prestaciones Médicas. Instituto Mexicano del Seguro Social, 2009;1-129.

  27. Physical status: the use and interpretation of anthropometry: report of a WHO expert committee. World Health Organ Tech Rep Ser 1995;854:1-452.

  28. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;28:2005-2012.

  29. Ali KM, McKeever BK, Saaddine BJ, Cowie CC, et al. Achievement of goals in U.S. diabetes care 1999-2010. N Engl J Med 2013;368:1613-1624.




2020     |     www.medigraphic.com